{"denoms":[{"counts":[{"groupId":"BG000","value":"622"},{"groupId":"BG001","value":"308"},{"groupId":"BG002","value":"930"}],"units":"Participants"}],"groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"BG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"BG001","title":"Leuprolide Acetate"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.75","value":"71.2"},{"groupId":"BG001","spread":"8.03","value":"71.0"},{"groupId":"BG002","spread":"7.84","value":"71.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"622"},{"groupId":"BG001","value":"308"},{"groupId":"BG002","value":"930"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"83"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"558"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"827"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"198"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"46"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"434"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"636"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"15"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"35"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"All randomized participants who received at least 1 dose of study drug in the primary analysis part of the study."}